サインイン 無料でサインアップします。

Last updated: 13 June 2024 at 6:36pm EST

David Smith Net Worth




The estimated Net Worth of David V Smith is at least 472 千$ dollars as of 11 December 2020. Mr. Smith owns over 22,000 units of Codexis stock worth over 244,502$ and over the last 18 years he sold CDXS stock worth over 62,220$. In addition, he makes 164,989$ as Independent Director at Codexis.

Mr. Smith CDXS stock SEC Form 4 insiders trading

David has made over 3 trades of the Codexis stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 22,000 units of CDXS stock worth 60,060$ on 11 December 2020.

The largest trade he's ever made was exercising 22,000 units of Codexis stock on 11 December 2020 worth over 60,060$. On average, David trades about 1,316 units every 26 days since 2006. As of 11 December 2020 he still owns at least 89,561 units of Codexis stock.

You can see the complete history of Mr. Smith stock trades at the bottom of the page.





David Smith biography

David V. Smith is Independent Director of the Company. Mr. Smith brings to our board of directors extensive experience in financial management, corporate finance and corporate governance. Mr. Smith serves as Executive Vice President and Chief Financial Officer at Five Prime Therapeutics, a publicly traded company focused on discovering and developing novel immuno-oncology protein therapeutics. Previously, Mr. Smith served as Chief Operating Officer of IntegenX, a privately held company focused on rapid DNA identification technology, until its acquisition by Thermo Fisher Scientific in March 2018. Prior to IntegenX, he was Executive Vice President and Chief Financial Officer of Thoratec Corporation, a publicly-traded company focused on the development of advanced therapy options for the treatment of heart disease, from December 2006 until July 2011. Prior to joining Thoratec in 2006, Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation, which he joined in 1999, and where he held a number of positions of increasing responsibility, including Vice President, Principal Accounting Officer and Controller, and Vice President of Finance. Mr. Smith served as the Vice President of Finance and Chief Financial Officer at Anergen Incorporated from 1997 to 1999. From 1988 to 1997, Mr. Smith served in various financial management positions with Genentech, Inc., both in the United States and Europe. He previously held finance positions at Syntex Corporation and IBM Corporation. Mr. Smith previously served as chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and of Perlegen Sciences, Inc. He holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in finance from Golden Gate University.

What is the salary of David Smith?

As the Independent Director of Codexis, the total compensation of David Smith at Codexis is 164,989$. There are 7 executives at Codexis getting paid more, with John Nicols having the highest compensation of 3,408,030$.



How old is David Smith?

David Smith is 60, he's been the Independent Director of Codexis since 2016. There are 7 older and 5 younger executives at Codexis. The oldest executive at Codexis Inc. is Thomas Baruch, 81, who is the Independent Director.

What's David Smith's mailing address?

David's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.

Insiders trading at Codexis

Over the last 15 years, insiders at Codexis have traded over 34,923,852$ worth of Codexis stock and bought 399,963 units worth 1,488,111$ . The most active insiders traders include Ventures Vii, Llc Vivo Vent...、Ventures Life Sciences 2000...、John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of 153,997$. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth 42,200$.



What does Codexis do?

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop



What does Codexis's logo look like?

Codexis Inc. logo

Complete history of Mr. Smith stock trades at Codexis、Five Prime Therapeutics Inc

日付
#
会社
 インサイダー
取引
取引
 株式 1株当たりの株価 合計金額 その後の株式数 ソース
11 Dec 2020 FPRX Five Prime Therapeutics Inc David V Smith
副社長、CFO
 オプション行使 22,000 16.14$ 355,080$
11 Dec 2020
89,561 ↗
11 Nov 2020 FPRX Five Prime Therapeutics Inc David V Smith
副社長、CFO
 オプション行使 22,000 18.00$ 396,000$
11 Nov 2020
85,389 ↗
3 Apr 2018 CDXS Codexis Inc. David V Smith
販売 6,000 10.37$ 62,220$
3 Apr 2018
56,679 ↗


Codexis executives and stock owners

Codexis executives and other stock owners filed with the SEC include: